Evotec SE ADR

Company Profile

Evotec SE ADR had its IPO on 2009-12-04 under the ticker symbol EVO.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evotec SE ADR has a staff strength of 4,952 employees.

Stock update

Shares of Evotec SE ADR opened at $11.49 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $11.46 - $11.65, and closed at $11.59.

This is a -0.6% slip from the previous day's closing price.

A total volume of 13,984 shares were traded at the close of the day’s session.

In the last one week, shares of Evotec SE ADR have slipped by -1.86%.

Evotec SE ADR's Key Ratios

Evotec SE ADR has a market cap of $4.04 billion, indicating a price to book ratio of 2.2976 and a price to sales ratio of 4.1528.

In the last 12-months Evotec SE ADR’s revenue was $751.45 million with a gross profit of $151.54 million and an EBITDA of $81.77 million. The EBITDA ratio measures Evotec SE ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evotec SE ADR’s operating margin was 2.71% while its return on assets stood at 0.57% with a return of equity of -13.7%.

In Q4, Evotec SE ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 28.7%.

Evotec SE ADR’s PE and PEG Ratio

Forward PE

89.2857

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.57 per share while it has a forward price to earnings multiple of 89.2857 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evotec SE ADR’s profitability.

Evotec SE ADR stock is trading at a EV to sales ratio of 3.8407 and a EV to EBITDA ratio of -19.0921. Its price to sales ratio in the trailing 12-months stood at 4.1528.

Evotec SE ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$2.26 billion

Total Liabilities

$337.71 million

Operating Cash Flow

$0

Capital Expenditure

$24.14 million

Dividend Payout Ratio

0%

Evotec SE ADR ended 2024 with $2.26 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.26 billion while shareholder equity stood at $1.19 billion.

Evotec SE ADR ended 2024 with $0 in deferred long-term liabilities, $337.71 million in other current liabilities, 176953000.00 in common stock, $-392377000.00 in retained earnings and $274.82 million in goodwill. Its cash balance stood at $415.16 million and cash and short-term investments were $729.98 million. The company’s total short-term debt was $16,381,000 while long-term debt stood at $328.30 million.

Evotec SE ADR’s total current assets stands at $1.07 billion while long-term investments were $150.33 million and short-term investments were $314.83 million. Its net receivables were $256.74 million compared to accounts payable of $97.28 million and inventory worth $29.83 million.

In 2024, Evotec SE ADR's operating cash flow was $0 while its capital expenditure stood at $24.14 million.

Comparatively, Evotec SE ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$11.59

52-Week High

$15.04

52-Week Low

$7.8

Analyst Target Price

$17

Evotec SE ADR stock is currently trading at $11.59 per share. It touched a 52-week high of $15.04 and a 52-week low of $15.04. Analysts tracking the stock have a 12-month average target price of $17.

Its 50-day moving average was $11.99 and 200-day moving average was $10.36 The short ratio stood at 1.26 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 73.9% are held by institutions.